Ozlem Goker-Alpan, MD, Founder and Chief Medical Officer at Lysosomal & Rare Disorders Research & Treatment Center (LDRTC) and discusses the latest develops in biomarker research and how biomarkers can improve how patients with lysosomal disorders, such as Gaucher disease and Fabry disease, are managed.
To obtain CME/CE credit for this program, go to www.checkrare.com
Support for this educational activity was provided by Takeda, Sanofi and Chiesi.
